advertisement
Abstract #25474 Published in IGR 12-1
Preliminary results following the use of a fixed combination of timolol-brimonidine in patients with ocular hypertension and primary open-angle glaucoma
Papaconstantinou D; Georgalas I; Kourtis N; Pitsas C; Karmiris E; Koutsandrea C; Ladas I; Georgopoulos GClinical Ophthalmology 2009; 3: 227-230
Purpose: The purpose of this prospective study was to evaluate the efficacy in intraocular pressure (IOP) control and the tolerance of a topically administered fixed combination of timolol-brimonidine in 50 patients with ocular hypertension and primary open-angle glaucoma. Methods: After determining a baseline IOP, the fixed combination timolol-brimonidine was used twice daily for two months, while IOP, ophthalmic signs, and/or symptoms were monitored. Results: The mean IOP value was decreased from 23.09 mm Hg ((plus or minus)1.98 SD) to 17.46 mm Hg ((plus or minus)1.47 SD) during the 1st month (paired Student's t test = 9.88 (kappa)(alpha)(iota) p < 0.001), and to 17.51 mm Hg ((plus or minus)1.43 SD) in the 2nd month. Between the 1st and 2nd month, no statistical difference was observed (paired Student's t test = 0.02 (kappa)(alpha)(iota) p > 0.1). In 8% of the patients during the 1st month and 10% of patients in the 2nd month, some ophthalmic signs were observed, while only mild ophthalmic symptoms were reported in 6% and 8% of the patients, respectively. Conclusions: In conclusion, the fixed combination of timolol-brimonidine has a satisfactory IOP-lowering effect without any serious side effects due to the topical use.
D. Papaconstantinou. Department of Ophthalmology, G Gennimatas Hospital of Athens, University of Athens, Athens, Greece. dpapaconstantinou@hotmail.com
Classification:
11.13.3 Betablocker and brimonidine (Part of: 11 Medical treatment > 11.13 Combination therapy)
